Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2061-2067

  McDowell, James A ^a   Lou, Yu ^a   Symonds, William S ^a   Stein, Daniel S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MIXTURE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RASH; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ZIDOVUDINE;

EID: 0033914965     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2061-2067.2000     Document Type: Article

References (18)

1. Burger, D. M., C. L. Kraaijeveld, P. L. Meenhorst, J. W. Mulder, C. H. W. Koks, A. Bult, and J. H. Beijnen. 1993. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 7:1581-1587.
2. Chittick, G. E., C. Gillotin, J. A. McDowell, Y. Lou, K. D. Edwards, W. T. Prince, and D. S. Stein. 1999. Abacavir (1592U89): absolute bioavailability and effect of food. Pharmacotherapy 19:932-942.
3. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averette, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
4. Drusano, G. L., D. Z. D'Argenio, W. Symonds, P. A. Bilello, J. McDowell, B. Sadler, A. Bye, and J. A. Bilello. 1998. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob. Agents. Chemother. 42:2153-2159.
5. Drusano, G. L., and D. S. Stein. 1998. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob. Agents Chemother. 42:358-361.
6. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
7. Hughes, W., J. A. McDowell, J. Shenep, P. Flynn, M. W. Kline, R. Yogev, W. Symonds, Y. Lou, and S. Hetherington. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother. 43:609-615.
8. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Symonds, Y. Lou, S. Hetherington, and S. LaFon. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob. Agents. Chemother. 43: 603-608.
9. Laskin, O., P. Miranda, and M. R. Blum. 1989. Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex. J. Infect. Dis. 159:745-747.
10. 14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43:2855-2861.
11. McDowell, J. A., G. E. Chittick, C. P. Stevens, K. D. Edwards, and D. S. Stein. 2000. Pharmcokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44:1686-1690.
12. Saag, M. S., A. Sonnerborg, R. A. Torres, D. Lancaster, B. G. Gazzard, R. T. Schooley, C. Romero, D. Kelleher, W. Spreen, S. LaFon, and the Abacavir Phase 2 Clinical Team. 1998. Antiretroviral effect and safety of abacavir and abacavir in combination with zidovudine in HIV-infected adults. AIDS 12: F203-F209.
13. Schuirmann, D. J. 1987. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharm. Biopharm. 15:657-680.
14. Staszewski, S., C. Katlama, T. Harrer, P. Massip, P. Yeni, A. Cutrell, S. M. Tortell, P. R. Harrigan, H. Steel, E. R. Lanier, and G. Pearce. 1998. A dose-ranging study to evaluate the safety and efficacy of three doses of abacavir (1592U89) alone or in combination with zidovudine and lamivudine in antiretroviral treatment naive subjects. AIDS 12:F197-F202.
15. Tadepalli, S. M., L. Puckett, S. Jeal, L. Kamocs, and R. P. Quinn. 1990. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clin. Chem. 36:897-900.
16. Tisdale, M., T. Alnadaf, and D. Cousens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents. Chemother. 41:1094-1098.
17. Wang, L. H., G. E. Chittick, and J. A. McDowell. 1999. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection. Antimicrob. Agents. Chemother. 43:1708-1715.
18. Weller, S., K. M. Radomski, Y. Lou, and D. S. Stein. 2000 Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob. Agents. Chemother. 44:2052-2060.